Bicycle Therapeutics
BCYC · NASDAQ
$3.60+$0.065 (+1.84%)TodayMarket closed ·
Prev close $3.54
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 26.5% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.5871 | -$0.72 | −22.6% |
| Q1 FY26 | -$0.6333 | -$0.87 | −37.4% |
| Q4 FY25 | -$0.9559 | -$0.29 | +69.7% |
| Q3 FY25 | -$1.10 | -$0.85 | +22.7% |
| Q2 FY25 | -$0.9706 | -$1.14 | −17.5% |
| Q1 FY25 | -$0.8591 | -$0.88 | −2.4% |
| Q4 FY24 | -$0.8757 | -$0.82 | +6.4% |
| Q3 FY24 | -$0.7973 | -$0.74 | +7.2% |
Earnings calls
- Morgan Stanley 23rd Annual Global Healthcare Conference
- 43rd Annual J.P. Morgan Healthcare Conference 2025
- Special Call - Bicycle Therapeutics plc
- Special Call - Bicycle Therapeutics plc
- Morgan Stanley 22nd Annual Global Healthcare Conference
- Goldman Sachs 45th Annual Global Healthcare Conference
- Barclays 26th Annual Global Healthcare Conference 2024
- Special Call - Bicycle Therapeutics plc
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.